Labile haemoglobin as a glycaemic biomarker for patient-specific monitoring of diabetes: mathematical modelling approach

Journal of the Royal Society, Interface
O León-TrianaV M Pérez-García

Abstract

Diabetes mellitus constitutes a major health problem and its clinical presentation and progression may vary considerably. A number of standardized diagnostic and monitoring tests are currently used for diabetes. They are based on measuring either plasma glucose, glycated haemoglobin or both. Their main goal is to assess the average blood glucose concentration. There are several sources of interference that can lead to discordances between measured plasma glucose and glycated haemoglobin levels. These include haemoglobinopathies, conditions associated with increased red blood cell turnover or the administration of some therapies, to name a few. Therefore, there is a need to provide new diagnostic tools for diabetes that employ clinically accessible biomarkers which, at the same time, can offer additional information allowing us to detect possible conflicting cases and to yield more reliable evaluations of the average blood glucose level concentration. We put forward a biomathematical model to describe the kinetics of two patient-specific glycaemic biomarkers to track the emergence and evolution of diabetes: glycated haemoglobin and its labile fraction. Our method incorporates erythrocyte age distribution and utilizes a large coh...Continue Reading

References

Mar 1, 1980·Clinical Chemistry·H Aleyassine
Apr 28, 2004·Diabetes Care·Lene R NielsenElisabeth R Mathiesen
Sep 14, 2004·Journal of Psychiatric Practice·Mohamed A Aziz, Susan Kenford
Jul 23, 2005·Annals of the New York Academy of Sciences·Vincent M MonnierSaul Genuth
Jul 23, 2005·Annals of the New York Academy of Sciences·Benjamin S SzwergoldPaul J Beisswenger
Jul 1, 2006·Biomedical Engineering Online·A Boutayeb, A Chetouani
Jun 10, 2008·Diabetes Care·David M NathanUNKNOWN A1c-Derived Average Glucose Study Group
Nov 26, 2008·American Journal of Hematology·Robert S Franco
Nov 17, 2009·Diabetes Research and Clinical Practice·R K SimmonsS J Griffin
Nov 10, 2010·Clinical Chemistry·Emmanuelle Corbé-GuillardPhilippe Gillery
Dec 4, 2010·Nano Letters·E KorenY Rosenwaks
Aug 9, 2011·European Journal of Epidemiology·Susanne MoebusKarl-Heinz Jöckel
Aug 27, 2011·Indian Journal of Pediatrics·Sedefgul Yuzbasioglu Ariyurek, Kıymet Aksoy
Jan 20, 2012·Annals of Laboratory Medicine·Nitin SinhaNaresh Gupta
May 23, 2012·Diabetes Research and Clinical Practice·José Escribano-Serrano, Alfredo Michán-Doña
May 23, 2012·Nature·Tony Scully
Dec 22, 2012·Diabetes·David B Sacks
Jan 9, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Denis Fouque, Fitsum Guebre-Egziabher
Jun 5, 2013·Mathematical Biosciences·Pasquale PalumboAndrea De Gaetano
Jun 12, 2013·Annales de biologie clinique·Florence MorelMichèle Fonfrède
Jan 1, 2014·Surgical Neurology International·Tamara KliotMichel Kliot
May 31, 2014·Journal of Diabetes Science and Technology·Edward R DamianoSteven J Russell
Oct 31, 2014·Journal of Diabetes Science and Technology·Mercedes Lorenzo-MedinaJesus Santana-Benitez
Sep 9, 2015·JAMA : the Journal of the American Medical Association·David M Nathan
Mar 31, 2016·SpringerPlus·W BoutayebN Zitouni
Apr 28, 2017·PLoS Computational Biology·David J AlbersLena Mamykina
Sep 20, 2017·Clinica Chimica Acta; International Journal of Clinical Chemistry·Ross MolinaroDouglas F Stickle

❮ Previous
Next ❯

Citations

Jan 19, 2022·Clinical Chemistry and Laboratory Medicine : CCLM·Joris R DelangheMarijn M Speeckaert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

© 2022 Meta ULC. All rights reserved